Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Tan, Lijun ^a   Liu, Jiangtao ^a   Liu, Xiuli ^a   Chen, Jie ^a   Yan, Zhijun ^a   Yang, Huifen ^a   Zhang, Daxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; AZASETRON; BENZODIAZEPINE DERIVATIVE; DEXAMETHASONE; FUSED HETEROCYCLIC RINGS; OLANZAPINE; OXAZINE DERIVATIVE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BICYCLO COMPOUNDS, HETEROCYCLIC; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; OXAZINES; QUALITY OF LIFE; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; VOMITING;

EID: 79953317123     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-131     Document Type: Article

References (17)

1. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-An update. Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M, Support Care Cancer 2005 13 80 84 10.1007/s00520-004-0718-y 15599601 (Pubitemid 40558162)
2. Should 5-hyroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. Geling O, Eichler HG, J Clin Oncol 2005 23 1289 1294 10.1200/JCO.2005.04.022 15718327 (Pubitemid 46202287)
3. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T, Support Care Cancer 2009 17 205 209 10.1007/s00520-008-0510-5 18839220
4. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high- dose cisplatin- the Aprepitant Protocol 052 Study Group. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant protocol 052 study group, J Clin Oncol 2003 21 4112 4119 10.1200/JCO.2003.01.095 14559886 (Pubitemid 46606178)
5. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, Aprepitant Protocol 054 Study Group, Cancer 2003 97 3090 3098 10.1002/cncr.11433 12784346 (Pubitemid 36676265)
6. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R, J Pain Symptom Manage 2003 25 578 582 10.1016/S0885-3924(03)00143-X 12782438 (Pubitemid 36629280)
7. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. Passik SD, Lundberg J, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Cooper M, Dugan W, J Pain Symptom Manage 2002 23 526 532 10.1016/S0885-3924(02)00391-3 12067777 (Pubitemid 34627037)
8. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. Passik SD, Kirsh KL, Theobald DE, Dicherson P, Trowbridge R, Gray D, Beaver M, Comparet J, Brown J, J Pain Symptom Manage 2003 25 485 488 10.1016/S0885-3924(03)00078-2 12727048 (Pubitemid 36506679)
9. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Passik SD, Navari RM, Jung SH, Nagy C, Vinsor J, Kirsh KL, Loehrer P, Cancer Invest 2004 22 383 388 10.1081/CNV-200029066 15493359 (Pubitemid 39310908)
10. A phase II trial of olanzapine for the prevention of chemptherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W, Support Care Cancer 2005 13 529 534 10.1007/s00520-004-0755-6 15700131 (Pubitemid 40933610)
11. Acute emesis: moderately emetogenic chemotherapy. Herrestedt J, koeller JM, Roilla F, Hesketh PJ, Warr D, Rittenberg C, Dicato M, Support Care Cancer 2005 13 97 103 10.1007/s00520-004-0701-7 15565276 (Pubitemid 40558164)
12. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, Koeller J, Olver I, Borjeson S, Ballatori E, Support Care Cancer 2005 13 85 96 10.1007/s00520-004-0699-x 15565277 (Pubitemid 40558163)
13. American Society of clinical oncology guideline for antiemetics in oncology: update 2006. American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM, J Clin Oncol 2006 24 2932 2947 10.1200/JCO.2005.04.8918 16717289 (Pubitemid 46630472)
14. Delayed emesis: moderately emetogenic chemotherapy. Roila F, Warr D, Clarck-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J, Support Care Cancer 2005 13 104 108 10.1007/s00520-004-0700-8 15549426 (Pubitemid 40558165)
15. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF, Br J Cancer 2006 94 1011 1015 10.1038/sj.bjc.6603048 16552437
16. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Dube S, Tollefson GD, Thase ME, Briggs SD, Van Campen LE, Case M, Tohen M, Bipolar Disord 2007 9 618 627 10.1111/j.1399-5618.2007.00491.x 17845277 (Pubitemid 47365630)
17. A randomized, double-blind, comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G, Depress Anxiety 2006 23 364 372 10.1002/da.20130 16710853 (Pubitemid 44619788)